CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug604 Colchicine plus symptomatic treatment (paracetamol) Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 70 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS SARS-CoV2 (COVID-19)

This is a phase 3 clinical trial, randomized, single-center, opened, controlled, to evaluate efficacy and safety of early administration of colchicines in patients older than 70 years, with high risk of pulmonary complications due to coronavirus SARS-CoV2 (COVID-19). An approximately number of 1000 subjects meeting all inclusion and none exclusion criteria will be randomized either to receive colchicines or symptomatic treatment with paracetamol during 21 days.

NCT04416334 SARS-CoV-2 Infection (COVID-19) Drug: Colchicine plus symptomatic treatment (paracetamol) Drug: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Measure: Number of participants who die due to COVID-19 infection

Time: 21 days post-randomization

Measure: Number of participants who require hospitalization due to COVID-19 infection

Time: 21 days post-randomization

Other Outcomes

Description: not delayed more than 48 hours from initial symptoms

Measure: A confirmed diagnosis from COVID-19 infection (by positive PCR test) will be mandatory .

Time: 48 hours


Related HPO nodes (Using clinical trials)